医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories announces the launch of Colesevelam Hydrochloride Tablets in the U.S. Market

2018年10月09日 PM10:04
このエントリーをはてなブックマークに追加


 

HYDERABAD, India & PRINCETON, N.J.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has launched Colesevelam HCl Tablets, USP, a therapeutic equivalent generic version of WELCHOL (colesevelam HCl) Tablets in the United States market approved by the U.S. Food and Drug Administration (USFDA).

The WELCHOL brand and generic had U.S. sales of approximately $471 million MAT for the most recent twelve months ending in August 2018 according to IMS Health*.

Dr. Reddy’s Colesevelam Hydrochloride Tablets is available in 625 mg with 180 count bottle size.

WELCHOL is a registered trademark of Daiichi Sankyo, Inc.

*IMS National Sales Perspective: Retail and Non-Retail MAT August 2018
RDY-1018-217

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181009005693/en/

CONTACT

Dr. Reddy’s Laboratories
INVESTOR RELATIONS
SAUNAK
SAVLA
saunaks@drreddys.com
Ph:
+91-40-49002135
or
MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
Ph:
+91-40- 49002121

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL HOLDINGS
  • NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
  • 研究显示,武田的登革热候选疫苗可保护4岁至16岁儿童,无论既往是否暴露于登革热
  • NINLAROTM (ixazomib)作为未接受干细胞移植的多发性骨髓瘤患者一线维持治疗的3期试验达到主要终点
  • 幹細胞移植歴のない多発性骨髄腫患者を対象としたファーストライン維持療法としてのニンラーロ(イキサゾミブ)の第3相試験で主要評価項目を達成